News | March 02, 2026
Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
The facility is expected to become operational by FY2028-29
The facility is expected to become operational by FY2028-29
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
This transaction fundamentally strengthens Scinai's CDMO platform
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Subscribe To Our Newsletter & Stay Updated
